Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) EBIT: ¥-161.2 Mil (TTM As of Dec. 2025)


SHSE:688505 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd SHSE:688505
67 GF Score
Price ¥7.38
GF Value ¥6.71
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co EBIT?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co SHSE:688505 67 EBIT is ¥-161.2 Mil as of Dec. 2025. GuruFocus rates SHSE:688505 with a GF Score™ of 67/100 and a GF Value™ of ¥6.71 (Fairly Valued). The stock has 2 warning signs investors should review.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was ¥-139.6 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was ¥-161.2 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's annualized ROC % for the quarter that ended in Dec. 2025 was -45.51%. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -102.97%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -3.39%.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co  (SHSE:688505) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-498.444 * ( 1 - 0% )/( (1181.929 + 1008.711)/ 2 )
=-498.444/1095.32
=-45.51 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2465.826 - 165.248 - ( 1118.649 - max(0, 176.888 - 1535.605+1118.649))
=1181.929

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2390.654 - 234.863 - ( 1147.08 - max(0, 245.621 - 1485.523+1147.08))
=1008.711

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-558.308/( ( (476.805 + max(126.053, 0)) + (481.319 + max(0.21399999999991, 0)) )/ 2 )
=-558.308/( ( 602.858 + 481.533 )/ 2 )
=-558.308/542.1955
=-102.97 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(253.669 + 31.036 + 18.236) - (165.248 + 0 + 11.64)
=126.053

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(201.335 + 33.213 + 5.9359999999999) - (234.863 + 0 + 5.407)
=0.21399999999991

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-161.179/4757.728
=-3.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co EBIT Related Terms

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co EBIT Historical Data

* Premium members only.

The historical data trend for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co EBIT Chart

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 216.98 133.83 100.59 6.05 -155.19

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Quarterly Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.11 -80.52 0.00 -21.60 -139.58

SHSE:688505 vs ZTS, UTHR: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EV-to-EBIT falls into.


SHSE:688505
67GF Score
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd SHSE:688505
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-161.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ¥-161.2 Mil mean?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) has a EBIT of ¥-161.2 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EBIT too high?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current EBIT is ¥-161.2 Mil. Overall, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EBIT compare to ZTS and UTHR?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EBIT of ¥-161.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current EBIT is ¥-161.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) is currently considered Fairly Valued. The stock's GF Value™ is ¥6.71, compared to a current price of ¥7.38 — trading 10% above its estimated fair value. The current EBIT is ¥-161.2 Mil. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505), the current EBIT is ¥-161.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥7.38 is trading 10% above its estimated GF Value™ of ¥6.71. GuruFocus considers Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co to be Fairly Valued.

Key valuation signals for SHSE:688505:

  • EBIT: ¥-161.2 Mil
  • GF Value™: ¥6.71 vs. price of ¥7.38 (10% above fair value)
  • GF Score™: 67/100 with 2 warning signs

No single metric tells the full story. See the SHSE:688505 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Business Description

Other Exchanges 01349:Hong Kong
Address 308 Cailun Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai, CHN, 201210
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. The company has launched it's four types of photodynamic drugs in China market, namely hematoporphyrin, aminolevulinic acid hydrochloride, Verteporfin and Hemoporfin. Geographically, it derives revenue from Mainland China.
67GF Score

Get the complete analysis for SHSE:688505

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥7.38
Price
¥6.71
GF Value